Access exceptional care for myelodysplastic syndromes (MDS) and other types of blood and bone marrow cancers at Montefiore Einstein Cancer Center. Our multi-disciplinary team has extensive experience caring for these rare cancers, which include refractory anemia and acute myeloid leukemia (AML) and occur when a person’s bone marrow produces large amounts of immature blood cells, called “blasts,” instead of healthy blood cells. 

Our MDS team has led the way in identifying groundbreaking cancer treatments and practices, including cutting-edge research that facilitated the U.S. Food and Drug Administration’s approval of Luspatercept (Reblozyl) for treatment of MDS–the first new medication for this illness in more than a decade.

We offer MDS treatment regimens with shorter but more frequent treatment touch points, making therapy more tolerable overall. And beginning in 2023, we will offer MDS patients CAR T-cell therapy, a pioneering treatment that helps the body’s own immune system better fight cancer. Our researchers and scientists are exploring ways to unleash the potential of this powerful treatment for all cancer types.

Our Myelodysplastic Syndromes Center is recognized as a national “center of excellence” by the MDS Foundation.

When you need myelodysplastic syndromes care, turn to our providers who are passionate about ending cancer and addressing your whole health needs.